Evidence map›Paper›PMID 26234920›Full record

ArticleScientific reports2015

Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers.

Prachi Anand, Alison O'Neil, Emily Lin, Trevor Douglas, Mandë Holford

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Genetically Engineered Microorganisms and Their Impact on Human Health.International journal of clinical practice · 2024
    Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. The Many Applications of Engineered Bacteriophages-An Overview.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Prachi Anand1] Hunter College-CUNY, Belfer Research Building, 413 E, 69th Street, New York, NY-10021 (USA) [2] The American Museum of Natural History, Central Park West 79th Street, New York, NY-10024 (USA).
Alison O'NeilIndiana University, 800 E. Kirkwood Ave., Bloomington, IN-47405 (USA).
Emily LinHunter College-CUNY, Belfer Research Building, 413 E, 69th Street, New York, NY-10021 (USA).
Trevor DouglasIndiana University, 800 E. Kirkwood Ave., Bloomington, IN-47405 (USA).
Mandë Holford1] Hunter College-CUNY, Belfer Research Building, 413 E, 69th Street, New York, NY-10021 (USA) [2] The American Museum of Natural History, Central Park West 79th Street, New York, NY-10024 (USA).
Hunter College · USIndiana University Bloomington · USAmerican Museum of Natural History · US

Funding

Basic and Translational Research Center for Reducing Health DisparitiesG12MD007599 · NIMHD · HUNTER COLLEGE · PI ANGULO, JESUS A · 2012 to 2017
$14.6M
NIMHD NIH HHS G12 MD007599NIMHD NIH HHS MD007599
6 · The paper itself

Abstract

The blood brain barrier (BBB) is often an insurmountable obstacle for a large number of candidate drugs, including peptides, antibiotics, and chemotherapeutic agents. Devising an adroit delivery method to cross the BBB is essential to unlocking widespread application of peptide therapeutics. Presented here is an engineered nanocontainer for delivering peptidic drugs across the BBB encapsulating the analgesic marine snail peptide ziconotide (Prialt®). We developed a bi-functional viral nanocontainer based on the Salmonella typhimurium bacteriophage P22 capsid, genetically incorporating ziconotide in the interior cavity, and chemically attaching cell penetrating HIV-Tat peptide on the exterior of the capsid. Virus like particles (VLPs) of P22 containing ziconotide were successfully transported in several BBB models of rat and human brain microvascular endothelial cells (BMVEC) using a recyclable noncytotoxic endocytic pathway. This work demonstrates proof in principle for developing a possible alternative to intrathecal injection of ziconotide using a tunable VLP drug delivery nanocontainer to cross the BBB.

Indexed as

Drug Delivery SystemsAmino Acid SequenceAnalgesics, Non-NarcoticAnimalsBacteriophage P22Blood-Brain BarrierCapsidCells, CulturedEndothelial CellsEndothelium, VascularHumansMolecular Sequence DataNanocompositesomega-Conotoxinsrab11 GTP-Binding Proteinsrab GTP-Binding ProteinsAnalgesics, Non-Narcoticomega-Conotoxinsrab11 GTP-Binding Proteinsrab GTP-Binding Proteinstat Gene Products, Human Immunodeficiency Virusziconotide

Identifiers

PMID26234920
PMCPMC4522602
OpenAlexW2270057972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.